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Abstract. Background/Aim: There are several definitions of
limited disease (LD) in small cell lung cancer (SCLC),
differing with respect to N3 disease accepted. We analyzed
patients from a randomized trial comparing two schedules of
thoracic radiotherapy (TRT) in LD SCLC to investigate
whether there were survival differences between N3
subcategories (n=144). Patients and Methods: Patients with
a baseline CT scan available were analysed. Patients received
four courses of cisplatin/etoposide and TRT of 45 Gy/30
fractions (twice daily) or 42 Gy/15 fractions (once daily).
Results: Median overall survival (OS) was 23.3 months in the
whole cohort. N3-patients (n=37) had shorter survival than
those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were
no significant OS-differences between the N3 subcategories,
but patients with metastases to two or more N3 regions had
shorter survival than other N3 patients (13.4 vs. 19.9 months;
p=0.011). Conclusion: There were no survival differences
between the N3 subcategories, suggesting that all N3 disease
should be considered as LD.
Chemotherapy is the basis treatment for small cell lung
cancer (SCLC). Concurrent radiotherapy improves survival
and is offered if all lesions can be included in a radiotherapy
field. i.e. limited disease (LD). Patients with more
widespread disease are classified as having extended disease
(ED) and receive chemotherapy alone (1).
There are, however, several definitions of LD. The first
definition was made by the Veterans Administration Lung
Study Group (VALSG) in 1957 and defined LD as disease
confined to one hemithorax, ipsilateral mediastinal, ipsilateral
hilar and ipsilateral supraclavicular lymph node metastases
(LNM) (2). The International Association for the Study of
Lung Cancer (IASLC) published an article in 1989
recommending that also contralateral mediastinal, contralateral
hilar and contralateral supraclavicular lymph nodes should be
considered LD, but this recommendation was based on data
on lung cancer patients in general and not only SCLC patients
(3). Furthermore, several trials published since 1989 have used
other definitions of LD. One study excluded patients with
contralateral hilar LNM, (4) others excluded both contralateral
hilar and contralateral supraclavicular LNM (5, 6).
Internationally, the TNM system is the most widely used
classification system for staging of cancer. It is also
recommended for staging of SCLC, but still most studies only
distinguish between LD and ED. Thus, there is little data
available to decide whether all subcategories of N3 disease
should be considered as LD; especially with respect to
ipsilateral and contralateral supraclavicular LNM. When the
latest revision of the TNM for lung cancer was performed, (7)
the committee only had complete data on extent of disease and
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treatment on 103 nonsurgical patients who had received
concurrent chemo- and radiotherapy for LD SCLC. There
were no survival differences between N categories among
nonsurgical patients and there were insufficient data to
investigate whether there were survival differences between
the different subcategories of N3 disease. Thus, when both the
seventh (2009) and eight edition (2015) of the TNM
classification of SCLC were published, it was recommended
to report the TNM stage in future studies of SCLC (7, 8).
We analyzed patients enrolled in a randomised phase II
trial comparing two schedules of thoracic radiotherapy (TRT)
in LD SCLC (9). The aims were to investigate the
distribution of TNM stage at baseline, and whether there
were survival differences between N categories or the
subcategories of N3 disease.
Materials and Methods
Approvals. The study was approved by the Regional Committee for
Medical Research Ethics in Central Norway, the Norwegian Social
Science Data Services and the Norwegian Directorate for Health
and Social Affairs.
Patients and treatment. Patients participating in a randomised phase
II trial comparing two schedules of TRT in LD SCLC were analysed
(9). Eligible patients gave written informed consent; were ≥18 years
old; ineligible for surgery; had disease confined to one hemithorax,
the mediastinum, contralateral hilar and supraclavicular (both ipsi-
and contralateral) lymph nodes; measurable disease according to
RECIST 1.0 (10); no other clinically active cancer; no malignant
pleural effusion (one negative cytology was required if pleural
effusion was observed); no prior radiotherapy to the chest; WHO
performance status 0-2; leukocytes ≥3.0×109/l; platelets ≥100×
109/l; bilirubin <1.5× ULN; and creatinine <125 μmol/l.
All patients were to receive four courses of cisplatin plus
etoposide and were randomised to receive TRT of either 45 Gy in 30
fractions (twice daily) or 42 Gy in 15 fractions (once daily) starting
3-4 weeks after start of the first chemotherapy course. Good
responders were offered prophylactic cranial irradiation of 30 Gy in
15 fractions. There were no significant differences in overall
response rates, progression free survival or overall survival (OS) (9).
Thus, all patients were analysed as one cohort in the present study.
Patients were eligible for the present study provided the baseline
staging CT scan was analysable, all pathological LNM were
irradiated they completed TRT and at least one chemotherapy course.
TNM stage. Extent of disease was assessed according to the TNM
v7 from contrast enhanced CT scans obtained before chemotherapy
commenced. All CT scans were reviewed by a thoracic radiologist
(MH). N3 disease was subcategorised as ipsilateral supraclavicular,
contralateral supraclavicular, contralateral hilar and contralateral
mediastinal LNM. An oncologist (TOH) and a medical physicist
(NL) checked whether all pathological lesions on the CT scans were
irradiated.
Analyses and statistical considerations. Survival time was defined
as time from inclusion in the study until death and was estimated
using the Kaplan-Meier method and compared using the log-rank
test. Cox multivariate analyses were conducted adjusting for
baseline characteristics (gender, age, performance status) (11, 12)
and TRT schedule. The significance level was defined as p<0.05.
Results
Patients. From May 2005 until January 2011, 157 eligible
patients were enrolled in the main trial. Of these, 144
(91.7%) were analyzed in the present study. A total of 13
patients were excluded due to missing CT scans (n=3),
missing CT radiotherapy planning scans (n=4), or
incomplete TRT (n=6). Patient characteristics are shown in
Table I. Mean age was 63.5 years (range=40-85 years), 74
(51.4%) were men, 121 (84.0%) had PS 0-1, 16 (11.1%) had
pleural fluid, 126 (87.5%) completed all four chemotherapy
courses and 65 (45.1%) received TRT of 45 Gy. Median
follow up was 91.1 months (range=61.0-128.8 months) and
32 patients were alive at the time of the survival analyses
(February 2016). 
Stage of disease. Distribution of TNM stage is listed in
Table II. Three patients (2.1%) had stage I disease, 17
(11.8%) stage II, 70 (48.6%) stage IIIA, and 54 (37.5%)
stage IIIB. Consequently, stage I and II patients were
analysed as one group.
Eighteen patients (12.5%) had T1 tumour, 18 (12.5%) T2,
42 (29.2%) T3 and 66 (45.8%) T4. Forty-one (33.0%)
patients had N0 disease, 13 (9.0%) N1, 53 (36.8%) N2 and
37 (25.7%) N3 (Table III). N3 involvement included
contralateral mediastinal LNM (n=25, 17.4%), contralateral
hilar LNM (n=11, 7.6%) and supraclavicular LNM (n=15,
10.4%). Among the patients with supraclavicular LNM, 13
had ipsilateral while only two had contralateral LNM. Thus,
these patients were analysed as one group. Twenty-five
patients had LNM in one N3 region (17.4%), 10 patients had
in two N3 regions (6.9%), and two had in three N3 regions
(1.3%) (Table III).
Survival analyses. In the whole cohort, median OS was
23.3 months and the 5-year survival was 26.4%. There
were no significant differences in median OS between men
and women (21.8 vs. 25.1 months; p=0.647), between PS
0-1 and PS 2 patients (23.6 vs. 22.6 months; p=0.365), or
those with pleural fluid vs. those without (31.0 vs. 22.6
months; p=0.404). 
Patients with stage IIIB had significantly shorter median
OS than those with lower disease stage (stage I-II: 33.8
months, IIIA: 33.0 months, IIIB: 18.8 months; p=0.007)
(Table II, Figure 1).
Median OS for the different subcategories of N3 is listed
in Table III. Patients with N3 disease (n=37) had significantly
shorter median OS compared with patients with N0-2 disease
(16.7 months vs. 33.0 months; p<0.001) (Figure 1), but there
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were no clinically relevant survival differences between the
subcategories of N3: contralateral hilar LNM: 15.5 months
(95%CI=6.4-24.7), contralateral mediastinal LNM: 16.7
months (95%CI=9.2-24.1) and supraclavicular LNM: 15.1
months (95%CI=12.0-18.2). However, no patients with
contralateral hilar LNM were alive after 5 years, while the
corresponding numbers for those with supraclavicular and
contralateral mediastinal LNM were 6.7% and 16.7%. A
statistical comparison was not performed since some patients
had involvement of more than one N3 region.
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Table I. Patient characteristics.
                                                                                    All patients (n=144)                                 N0-2 (n=107)                                       N3 (n=37)
                                                                                   n                              %                           n                           %                          n                           %
Age, years
    Mean, (SD), (range)                                                63.5±8.71, (40-85)                               62.8±8.57 (40-79)                              65.6±8.9 (44-85)
Gender
    Male                                                                      74                           51.4                         51                         47.7                       23                        62.2
    Female                                                                  70                           48.6                         56                         52.3                       14                        37.8
Performance status
    0                                                                            47                           32.6                         40                         37.4                        7                         18.9
    1                                                                            74                           51.4                         53                         49.5                       21                        56.8
    2                                                                            23                           16.0                         14                         13.1                        9                         24.3
Pleural fluid
    Yes                                                                         16                           11.1                         12                         11.2                        4                         10.8
    No                                                                        128                          88.9                         95                         88.2                       33                        89.2
Thoracic radiotherapy
    42 Gy/15 fractions                                               79                           54.9                         60                         56.1                       19                        51.4
    45 Gy/30 fractions                                               65                           45.1                         47                         43.9                       18                        48.6
Completed 4 courses of chemotherapy
    Yes                                                                       126                          87.5                         95                         88.8                       31                        83.8
    No                                                                         18                           12.5                         12                         11.2                        6                         16.2
Table II. TNM stage.
                                No. of pts. (n=144)                 %                Median OS (months)                95%CI                   p-Value              5-year survival (%)
Stage I-II                               20                             13.9                            33.8                           13.6-53.9                   0.007                              40
Stage I
  T1N0                                    1                                .7                                                                                                                                            
  T2N0                                    2                               1.4                                                                                                                                           
Stage II
  T1N1                                    4                               2.8                                                                                                                                           
  T2N1                                    0                                0                                                                                                                                            
  T3N0                                   13                              9.0                                                                                                                                           
Stage IIIA                              70                             48.6                            33.0                           20.6-45.3                                                        31.4
  T1N2                                    9                               6.3                                                                                                                                           
  T2N2                                   12                              8.3                                                                                                                                           
  T3N1                                    7                               4.9                                                                                                                                           
  T3N2                                   15                             10.4                                                                                                                                          
  T4N0                                   25                             17.4                                                                                                                                          
  T4N1                                    2                               1.4                                                                                                                                           
Stage IIIB                              54                             37.5                            18.8                           15.3-22.4                                                        14.8
  T1N3                                    4                               2.8                                                                                                                                           
  T2N3                                    4                               2.8                                                                                                                                           
  T3N3                                    7                               4.9                                                                                                                                           
  T4N2                                   17                             11.8                                                                                                                                          
  T4N3                                   22                             15.3
There was a trend towards inferior median OS among the
patients with involvement of more than one N3 region (one
N3 region: 19.9 months, two or three N3 regions: 13.4
months; p=0.052) (Figure 1). Five-year survival for patients
with involvement of one N3 region was 20.0% compared
with 0.0% for those with involvement of two or three N3
regions (Table III).
There were no significant survival differences between the
T categories (Table III, Figure 1). Median OS was 21.7
months for T1 tumours, 38.8 months for T2, 29.5 months for
T3, and 21.7 months for T4 (p=0.356).
Multivariate analyses showed that N3 disease (HR=1.94;
95%CI=1.27-3.0; p=0.002), stage of disease (HR=1.52;
95%CI=1.14-2.04; p=0.048), and involvement of 2-3 N3
ANTICANCER RESEARCH 38: 871-876 (2018)
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Figure 1. Kaplan–Meier survival plots for (A) N0-2 disease vs. N3 disease, (B) T stage, (C) stage of disease and (D) involvement of one N3 region
vs. two or three N3 regions. p-Values were calculated using the log-rank test.
Table III. Median OS and 5-year survival for N3 lymph node metastases.
                                                                        N               %              Median OS (months)              95%CI                p-Value             5-year survival (%)
T1                                                                   18             12.5                          21.7                          14.4-29.0               0.356                           27.8
T2                                                                   18             12.5                          38.8                          21.5-56.2                                                    38.9
T3                                                                   42             29.2                          29.5                          18.4-40.6                                                    28.6
T4                                                                   66             45.8                          21.7                          16.2-27.3                                                    21.2
N0-2                                                              107            74.3                          33.0                          29.7-36.2              0.001*                          30.8
N3                                                                   37             25.7                          16.7                          12.2-21.1                                                    13.5
Supraclavicular LNM                                    15             10.4                          15.1                          12.0-18.2                                                     6.7
Contralateral mediastinal LNM                    25             17.4                          16.7                           9.2-24.1                                                     16.7
Contralateral hilar LNM                               11              7.6                           15.5                           6.4-24.7                                                       0
One N3 station LNM                                    25             17.4                          19.9                          16.4-23.4               0.052                           20.0
Two or three N3 station LNM                      12              8.3                           13.4                           6.4-20.4                                                       0
*Significantly different from N3.
regions (HR=3.61; 95%CI=1.91-6.81; p=0.011) remained
significant negative prognostic factors. None of the baseline
characteristics, T stage, pleural fluid or TRT schedule were
independent prognostic factors.
According to RECIST 1.1, lymph nodes with a short axis
diameter of ≥15 mm are considered pathological. There were
no significant differences when rerunning the analyses defining
≥15 mm as the criterium for pathological lymph nodes.
Discussion
In this study of patients with LD SCLC receiving concurrent
chemo- and radiotherapy, we found that those with N3
disease had a significantly shorter survival than patients with
N0-2 disease. There were no survival differences between
the subcategories of N3 disease, but those with involvement
of two or three N3 regions had significantly worse prognosis. 
To our knowledge, this is the first study reporting detailed
T and N data including subcategories of N3 in a cohort of
LD SCLC patients who all received standard chemotherapy
and established schedules of concurrent thoracic
radiotherapy. According to the authors, there were
insufficient data to determine whether there were survival
differences between the subcategories of N3 disease in the
databases used for the 7th and 8th revision of the TNM for
SCLC (7, 8). 
Our results may, in some aspects, differ from what was
found in the article presenting the 8th revision of the TNM
for SCLC (7). In that paper, T stage was a significant
prognostic factor among non-surgical patients, while N status
was not, and there was no survival difference between stage
IIIA and IIIB. The results are, however, not necessarily
comparable since a large proportion of the patients in the
TNM article had undergone surgery, and details on treatment
was not available for all nonsurgical patients. We only
analyzed non-surgical patients who received concurrent
chemoradiotherapy.
A limitation of the study is the sample size, especially in
the N3 subgroups. However, our sample size is still larger
than the number of patients who received both chemotherapy
and TRT in the database used for the latest TNM revision for
SCLC (8th edition) (7). In this database (n=5002) treatment
data were available for only 11% of inoperable patients, and
among these 2931 nonsurgical patients, it was only
confirmed that 103 patients received both chemo- and
radiotherapy.
Another limitation is that positron emission tomography
(PET CT) was not used for staging of disease in our study.
Studies conducted after our trial was initiated have shown
that PET CT identifies pathological lesions better than CT
scans, providing more accurate staging 13). However, few
other published trials of TRT in LD SCLC have yet used
PET CT for staging (4, 5, 6, 14).
Patient characteristics, TNM distribution and overall
survival in our study cohort are similar to other studies of
chemoradiotherapy in LD SCLC, (4,5,6,14) we used the
widest definition of LD (IASLC), (3) had no restrictions
regarding comorbidity or age, and 16% had PS 2. Thus, we
consider the study population representative for LD SCLC
patients receiving chemoradiotherapy.
We were not able to detect differences in survival between
the subcategories of N3 disease. Thus, until other data
emerge, it appears reasonable to consider all N3 disease as
LD. The overall survival for all subcategories of N3 disease
were longer than in studies of ED SCLC, (15) with the
possible exception of patients with LNM to two or more N3
stations. It is also noteworthy that none of the patients with
contralateral hilar LNM were alive after 5 years, but the
number of patients was small. Our data suggest that
incorporating the subcategories and number of involved N3
regions might add to the prognostic value of the TNM
staging system, but this needs to be confirmed in larger
cohorts. Furthermore, considering the improvement in
staging methods with the introduction of PET CT and
endobronchial ultrasound guided transbronchial needle
aspiration, improved radiotherapy techniques, and the
demonstrated benefit of TRT in some ED SCLC patients, the
definition of patients who should be offered TRT may be
challenged, but requires large databases containing detailed
information about disease extent and treatment administered.
In conclusion, patients with N3 disease had inferior
survival compared to those with N0-2 disease, but there were
no survival differences between the N3 subcategories. Our
study indicates that all N3 lymph node metastases should be
considered as limited disease, with the possible exception of
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